SG Americas Securities Trims CONMED Corporation Stake

Investment firm reduces holdings in medical device company by nearly 80%

Apr. 13, 2026 at 8:54am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white macro photograph of the inner workings and mechanical components of a medical device, conveying the complex and precise nature of CONMED's products.An extreme close-up of CONMED's specialized surgical equipment highlights the company's technical expertise and manufacturing capabilities.Utica Today

SG Americas Securities LLC has reduced its stake in CONMED Corporation (NYSE: CNMD) by 79.8% during the fourth quarter, according to a recent SEC filing. The investment firm now owns 12,876 shares of the medical device company's stock, down from 63,894 shares previously.

Why it matters

This move by a major institutional investor signals potential concerns about CONMED's performance or outlook, which could impact the company's stock price and future growth prospects. Tracking changes in institutional ownership is an important indicator for investors to monitor.

The details

According to the 13F filing, SG Americas Securities sold 51,018 shares of CONMED stock during the fourth quarter. The firm's remaining 12,876 shares were valued at $523,000 at the end of the period. CONMED, which develops and markets surgical devices and accessories, has seen its stock price decline over the past year amid broader market volatility.

  • SG Americas Securities filed its 13F report for the fourth quarter of 2025 on April 13, 2026.
  • The firm reduced its CONMED stake during the three-month period ending December 31, 2025.

The players

SG Americas Securities LLC

An investment management firm that has reduced its holdings in medical device company CONMED Corporation.

CONMED Corporation

A global medical technology company that develops and markets surgical devices and accessories, primarily for minimally invasive procedures.

Got photos? Submit your photos here. ›

The takeaway

Investors will be closely watching CONMED's financial performance and any further changes in institutional ownership, as these factors could significantly influence the company's stock price and future direction.